Immunovant Sciences GmbH
19
5
8
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
26.3%
5 terminated/withdrawn out of 19 trials
50.0%
-36.6% vs industry average
26%
5 trials in Phase 3/4
100%
5 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
Role: lead
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Role: lead
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Role: lead
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Role: lead
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Role: lead
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
Role: lead
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Role: lead
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Role: lead
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Role: lead
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Role: lead
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Role: lead
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
Role: lead
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Role: lead
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Role: lead
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Role: lead
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Role: lead
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
Role: lead
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
Role: lead
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
Role: lead
All 19 trials loaded